These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 7699886)

  • 1. [Molecular analysis of multiple myeloma cells].
    Yasuga Y; Hirosawa S
    Nihon Rinsho; 1995 Mar; 53(3):564-7. PubMed ID: 7699886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular genetics of malignant insulinoma.
    Pavelic K; Hrascan R; Kapitanovic S; Vranes Z; Cabrijan T; Spaventi S; Korsic M; Krizanac S; Li YQ; Stambrook P; Gluckman JL; Pavelic ZP
    Anticancer Res; 1996; 16(4A):1707-17. PubMed ID: 8712689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenes in multiple myeloma: point mutation of N-ras.
    Paquette RL; Berenson J; Lichtenstein A; McCormick F; Koeffler HP
    Oncogene; 1990 Nov; 5(11):1659-63. PubMed ID: 2267133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 and RAS gene mutations in multiple myeloma.
    Portier M; Molès JP; Mazars GR; Jeanteur P; Bataille R; Klein B; Theillet C
    Oncogene; 1992 Dec; 7(12):2539-43. PubMed ID: 1461658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular and molecular genetic features of myeloma and related disorders.
    Durie BG
    Hematol Oncol Clin North Am; 1992 Apr; 6(2):463-77. PubMed ID: 1582985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated c-myc messenger RNA in multiple myeloma cell lines.
    Fourney R; Palmer M; Ng A; Dietrich K; Belch A; Paterson M; Brox L
    Dis Markers; 1990; 8(3):117-24. PubMed ID: 1980237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAS mutations are uncommon in multiple myeloma and other monoclonal gammopathies.
    Martín P; Santón A; García-Cosío M; Bellas C
    Int J Oncol; 2005 Oct; 27(4):1023-8. PubMed ID: 16142319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6.
    Billadeau D; Liu P; Jelinek D; Shah N; LeBien TW; Van Ness B
    Cancer Res; 1997 Jun; 57(11):2268-75. PubMed ID: 9187131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered expression of growth-regulated protooncogenes in human malignant plasma cells.
    Palumbo AP; Pileri A; Dianzani U; Massaia M; Boccadoro M; Calabretta B
    Cancer Res; 1989 Sep; 49(17):4701-4. PubMed ID: 2667753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The biology of multiple myeloma.
    Drach J; Kaufmann H; Urbauer E; Schreiber S; Ackermann J; Huber H
    J Cancer Res Clin Oncol; 2000 Aug; 126(8):441-7. PubMed ID: 10961386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of oncogenes and suppressor genes in lung cancer and bronchial lesions from high risk group].
    Awaya Y; Hiyama K; Yamakido M
    Nihon Kyobu Shikkan Gakkai Zasshi; 1992 Dec; 30 Suppl():39-41. PubMed ID: 1306237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A high frequency of N-RAS oncogene mutations in multiple myeloma.
    Tanaka K; Takechi M; Asaoku H; Dohy H; Kamada N
    Int J Hematol; 1992 Oct; 56(2):119-27. PubMed ID: 1421173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAS gene mutations in multiple myeloma and related monoclonal gammopathies.
    Matozaki S; Nakagawa T; Nakao Y; Fujita T
    Kobe J Med Sci; 1991 Feb; 37(1):35-45. PubMed ID: 1921261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protooncogene expression in normal, preleukemic, and leukemic murine erythroid cells and its relationship to differentiation and proliferation.
    Robert-Lézénès J; Meneceur P; Ray D; Moreau-Gachelin F
    Cancer Res; 1988 Jul; 48(14):3972-6. PubMed ID: 3164254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiation primary response genes and proto-oncogenes as positive and negative regulators of terminal hematopoietic cell differentiation.
    Liebermann DA; Hoffman B
    Stem Cells; 1994 Jul; 12(4):352-69. PubMed ID: 7951003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.
    Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T
    Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Genetic alterations in the genesis and development of ovarian cancer].
    Okamoto A; Yokoyama S; Terashima Y
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):1971-6. PubMed ID: 1358031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific expression of cellular oncogenes c-myc and c-myb in T-cell lines established from three types of bovine lymphosarcomas.
    Ishiguro N; Matsui T; Shinagawa M
    Am J Vet Res; 1993 Dec; 54(12):2010-4. PubMed ID: 8116930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relevance of Ras gene mutations in the context of the molecular heterogeneity of multiple myeloma.
    Intini D; Agnelli L; Ciceri G; Ronchetti D; Fabris S; Nobili L; Lambertenghi-Deliliers G; Lombardi L; Neri A
    Hematol Oncol; 2007 Mar; 25(1):6-10. PubMed ID: 17036375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amplification of the c-myc and the pvt-like region in human multiple myeloma.
    Bakkus MH; Brakel-van Peer KM; Michiels JJ; van 't Veer MB; Benner R
    Oncogene; 1990 Sep; 5(9):1359-64. PubMed ID: 2216459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.